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Abstract
Pregnancy and peripartum increase the risk of venous thromboembolism (VTE) 
by many folds. Interestingly, the VTE is more common during the pregnancy, whereas 
the pulmonary embolism is more frequent in postpartum period. There are various risk 
factors for the VTE and pulmonary embolism in these patients. The important risks are 
improper thromboprophylaxis, obesity, and multigravida. The clinical parameters and 
the d-dimer are not used for diagnosis of thromboembolism during pregnancy and in 
the postpartum period. The compression ultrasonography (CUSG) is commonly used 
for VTE diagnosis; for the pulmonary embolism diagnosis, one has to consider the 
radiation hazard to the fetus as well as to the mothers. Ventilation/perfusion scan is the 
imaging of choice for patient who has respiratory signs with normal chest radiograph. 
If chest X-ray is abnormal with suspicion of peripartum pulmonary embolism (PPE), 
the choice should be computed tomographic angiography. Heparin and its derivatives 
remained the anticoagulation of choice for the treatment of VTE as well as the PPE, as it 
is a shorter acting, easy to reverse with protamine sulfate. Proper thromboprophylaxis is 
the key for prevention of VTE and peripartum pulmonary embolism.
Keywords: computed tomography, heparin, low-molecular-weight heparin, 
pregnancy, peripartum, pulmonary embolism, thrombolysis, ultrasound,  
ventilation/perfusion scan and warfarin
1. Introduction
The first description of a case compatible with deep venous thrombosis (DVT) 
appears during the Middle Ages: Guillaume de Saint-Pathus in 1271 reported as “La 
vie et les miracles de Saint Louis.” It was about a 20-year-old Norman cobbler who 
suffered unilateral pain and swelling of the right calf that subsequently extended 
up to the thigh, and his surgeon advised him to wait and see. Patient’s symptoms 
worsened, and he developed a leg ulcer. He was advised to visit the tomb of King 
Saint Louis. He spent days praying near the tomb and then decides to collect the 
dust below the stone covering the tomb and applied it directly to the ulcer. He was 
miraculously healed after this direct application and reported to survive. On the 
basis of the writings from the New Testament, Brenner surmised that Jesus Christ 
himself may have suffered from a pulmonary embolism (PE), but this hypothesis 
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is debated. Avicenna warned against the risk of “particle migration” after the 
vein surgery: consistent with embolization of a DVT [1]. During the Renaissance 
physicians hypothesized that pregnancy-related DVT, which was the leading or 
even only cause of reported DVT at that time, was the consequence of retention of 
“evil humors.” It was also thought that postpartum DVT was caused by retention 
of unconsumed milk in the legs (“milk leg”). Thus in the 1700s, breastfeeding was 
encouraged to prevent DVT, and bloodletting technique was used to treat DVT [1]. 
Virchow in 1856 demonstrated the relationship between DVT and fatal PE. The 
major pathologic mechanisms of venous thrombosis were first summarized in the 
famous Virchow’s triad theorized by Andral in 1831, and in the 1920s, a consensus 
appeared regarding the three factors contributing to thrombosis: stasis, vessel wall 
alteration, and hypercoagulability: during this period a number of treatment break-
throughs were discovered by accident revolutionizing the DVT management [1].
Patients in pregnancy and postpartum are at the higher risk of thromboembolic 
phenomenon, particularly postpartum period. These risks are due to the normal 
or physiological changes of pregnancy to save the blood loss of parturition. These 
physiological changes will lead to the Virchow’s triad. The peripartum pulmonary 
embolism (PPE) is 10 times more common than the nonpregnant females in the 
same age group. The risk of PPE increases by 20-fold in the postpartum period [2]. 
The incidence of pulmonary embolism during pregnancy and postpartum is 1.59 per 
100,000 maternities. The venous thromboembolism (VTE) complicates 1–2/1000 
pregnancies. Interestingly the VTE is common throughout all trimesters of pregnan-
cies in contrast to pulmonary embolism which is most common in the postpartum 
period [3]. As described above, the VTE is equally distributed in all three trimesters of 
pregnancy; it is frequent in pelvic/iliofemoral veins and more common on the left side 
as there is compression on left iliac vein which is crossed by the right common iliac 
artery called May-Thurner syndrome (Figure 1). This is in contrast to the nonpreg-
nant females where the VTE is common in the popliteal femoral venous system [4].
2. Risk factors
There are various risk factors for VTE and PPE in pregnancy and postpartum 
period. These risk factors are divided into three categories as follows (Table 1).
High-risk patients are mainly those patients with previous history of VTE, congeni-
tal, and acquired thrombophilia pregnant patients. The obstetric risk factors for VTE are 
multiple pregnancies, surgical delivery, and patients with the postpartum hemorrhage. 
The transient risk factors for the development of VTE and PPE are ovarian hyperstimu-
lation syndrome, hyperemesis gravidarum, severe dehydration, surgical interventions, 
and immobility. There can be more than one risk factor for VTE in one patient. Obesity 
and multiple pregnancies were the risk factors for VTE in Middle East population [5].
Figure 1. 
May-Thurner Syndrome (narrowing of left iliac vein by crossing right iliac artery).
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3. Pathophysiology
The various physiological changes of pregnancy in combination with venous sta-
sis and vascular injury (normal delivery as well as surgical deliveries) will form the 
Virchow’s triad and a higher risk for thromboembolic phenomenon in pregnancy 
and postpartum period.
Venous stasis results from a hormonally induced decrease in venous tone and 
obstruction of venous flow by the enlarging uterus. A reduction of venous flow 
velocity of 50% occurs in the legs by 29 weeks of gestation and remains up to 
6 weeks postpartum. In pregnant and postpartum women, the left lower extremity 
is the most common site of DVT. The anatomic reasons (compression of the left 
common iliac vein by the right common iliac artery which is accentuated by the 
enlarging uterus) have been attributed [6]. Endothelial damage in the pelvic veins 
occurs from the delivery or from venous hypertension. Normal pregnancy induces a 
hypercoagulable state. This hypercoagulable state is multifactorial and is thought to 
be due to a combination of physical and hormonal factors and hematologic changes. 
The physical and hormonal changes of pregnancy begin early in the first trimester. 
Progesterone-mediated increases in venous distensibility and capacity are apparent 
in the first trimester that result in increased venous stasis [6].
During pregnancy there will be increased in procoagulant factor concentra-
tion (factor VII, VIII, X, and vWF); there is a fivefold increase in the plasminogen 
activator inhibitor type 1 levels, whereas there is a decrease in natural anticoagulant 
particularly protein S and the fibrinogen levels. There is an increased resistance 
to protein C activity. These changes during pregnancy and parturition are for the 
protection from massive blood loss during delivery. The dark side of it is that it 
increases the risk for VTE and pulmonary embolism during pregnancy and in the 
peripartum period [7].
Pulmonary embolism (PE) can occur if venous thrombi detach and emblaze 
to the pulmonary circulation. It causes pulmonary vascular occlusion and impairs 
gas exchange and circulation. Larger emboli wedge in the main pulmonary artery, 
whereas smaller emboli occlude the peripheral arteries and peripheral PE can 
Higher risk
Congenital or acquired thrombophilia
History of VTE
Obesity
Multigravida
Maternal smoking
Elderly parturient
Obstetric risk
Multiple pregnancies
Assisted reproduction
Cesarean section
Postpartum hemorrhage
Transient risk
Ovarian hyperstimulation syndrome
Hyperemesis gravidarum
Surgical intervention in the peripartum
Immobility
Systemic infections
Table 1. 
Categories of risk for VTE in pregnancy.
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cause pulmonary infarction. Obstruction of the pulmonary flow creates dead space 
ventilation due to alveolar ventilation exceeds pulmonary capillary blood flow. This 
contributes to ventilation-perfusion mismatch with increasing in pulmonary vascular 
resistance. As the pulmonary artery systolic pressure increases, the right ventricular 
afterload increases leading to a right ventricular impairment. When right ventricular 
failure progresses, the left ventricular filling may be impaired, and it may rapidly 
progress to myocardial ischemia which may occur secondary to inadequate coronary 
artery filling with potential for hypotension, syncope, electromechanical dissocia-
tion, or sudden death. The humoral mediator serotonin and thromboxane are released 
from activated platelets and trigger vasoconstriction in the healthy lungs [6].
4. Diagnosis
It is of vital importance to accurately diagnose the VTE and PPPE to avoid 
the misdiagnosis and increase the morbidity and mortality, whereas when falsely 
diagnosed, it will unnecessarily increase the risk of bleeding and increased morbid-
ity and mortality.
The clinical manifestations such as tachypnea, dyspnea, and tachycardia may 
be considered as related to pregnancy. The d-dimer are not of help in pregnant and 
postpartum patients, as it raises changes of normal pregnancy and takes weeks in 
postpartum to return to the normal limits [8].
Arterial blood gas (ABG) may show respiratory alkalosis, and 12 lead ECG may 
be useful as it may show changes in right-sided leads. These tests are neither sensi-
tive nor specific in the diagnosis of pulmonary embolism.
4.1 Echocardiography
Echocardiography is a noninvasive procedure and may show the indirect signs 
called “McConnell” sign that is the right ventricular hypokinesia and hypercontrac-
tility of the apical wall with raised pressures [9]. Echocardiograph also helps in rule 
of other possible etiologies such as peripartum cardiomyopathy.
Imaging studies are the corner stone for the diagnosis of the pulmonary embo-
lism; it is of vital importance that while considering the selection of imaging studies, 
one has to be very careful in its effects not only on fetus but equally important for 
mothers as well.
4.2 Chest X-ray
All patients suspected of PE will have a chest X-ray; in pregnant patient we 
can cover the abdomen and do a chest X-ray. Normal chest X-ray with respiratory 
symptoms should raise the high index of suspicion for the pulmonary embolism. 
Presence of the wedge-shaped opacity with pleural base is considered as hallmark 
for the diagnosis of PE in chest X-ray, but this also found to be not sensitive or 
specific for the pulmonary embolism [10].
4.3 Bilateral compression sonography
Bilateral compression sonography of the lower limbs has an advantage of por-
tability, noninvasive and no radiations; at the same time it diagnoses the VTE with 
accuracy. If it is positive and shows thromboembolic lesion, we have to start the 
anticoagulation therapy. But if it is negative, then we have to proceed with further 
diagnostic imaging studies [11].
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4.4 Ventilation/perfusion (V/Q ) scan
Those pregnant and postpartum patients with normal chest X-ray and 
suspected to have PPPE, the ventilation/perfusion (V/Q ) scan is the imaging 
of choice. A positive V/Q scan will demonstrate a mismatch perfusion pattern. 
The low and high probability scans are diagnostic, as the low probability scan 
has up to 6% chances of having pulmonary embolism, whereas the high prob-
ability scan had up to 96% chances of PE. As most of the parturient are healthy 
with a normal chest X-ray, the V/Q scan has a higher diagnostic accuracy for the 
diagnosis of PE [12].
4.5 CT pulmonary angiography (CTPA)
CTPA is increasingly used, and it is a sensitive and specific imaging study for the 
diagnosis of the pulmonary embolism in both pregnant and nonpregnant patients 
(Figure 2). It is also an imaging study of choice in patients suspected of pulmonary 
embolism with an abnormal chest X-ray as it gives alternative diagnosis if there is 
no pulmonary embolism. In pregnant patients, there is an increase in cardiac output 
and blood volume; hence, there can be issues with quantification and time of 
intravenous contrast is difficult [13].
4.6 Magnetic resonance pulmonary angiography (MRPA)
It is not much evaluated in pregnancy, despite of MRI contrast (gadolinium) has 
no evidence of causing fetal teratogenicity. In contrast, it is highly sensitive and spe-
cific in diagnosis of PE in the general population (up to 92% and up to 100%) [14].
4.7 Digital subtraction angiography (DSA)
It is a historical gold standard for the diagnosis of PE. It is rarely performed nowa-
days and it also not evaluated in the pregnant population. In retrospective subpopula-
tion evaluation, it was found that the DSA is less sensitive than CTPA with a higher 
reports of false negativity [15].
Figure 2. 
CTPA showing pulmonary embolism.
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Figure 3. 
Diagnostic algorithm for PPE.
In the concluding lines about the selection of imaging studies, the fear of fetal 
radiation exposure and adverse effects should not deprive the mother of timely and 
accurate diagnosis of PPE. Each of the imaging study has advantages and disadvantage 
(Table 2). Better approach is to follow the diagnostic algorithm (Figure 3) [16].  
Table 2. 
Risk and benefits of various imaging studies.
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The V/Q imaging is of choice when chest X-ray is normal; CTPA should have upper 
hand if chest X-ray is abnormal, but it had more radiation exposure to the maternal 
breast, with slightly increased risk of carcinoma, and it will increase the lifetime risk 
for breast cancer by 13.6% [17].
4.8 Single-photon emission CT ventilation/perfusion scan (SPECT V/Q )
The use of SPECT V/Q is superior to planar V/Q scintigraphy and CTPA. In nuclear 
medicine, the transition from planar techniques to SPECT has led to improvements 
in sensitivity and diagnostic accuracy. The published literature on SPECT V/Q has 
consistently shown improvements in sensitivity and specificity. The CTPA sensitivity in 
prospective multicenter PIOPED 2 study suggests that even with current-generation CT 
technology, CTPA fails to diagnose PE in approximately one in every six patients. If the 
limitations of CTPA in the detection of smaller emboli and larger emboli are missed, it is 
suggested that emboli not detected by CTPA are not clinically significant; it may not be 
true in patients with cardiorespiratory disease, and in these patients in particular, accu-
rate detection is of vital importance. The PIOPED 2 study demonstrated that the CTPA 
accuracy falls further, if the scan results do not correlate with the clinical likelihood of 
disease, and in these circumstances, the incidence of false-positive and false-negative 
results is significant SPECT V/Q. Using Technegas also has the advantage of an extremely 
high-negative predictive value, reaching 98.5% in a large prospective series [18].
In PIOPED 2 study, over 40% of patients did not undergo CTPA because of renal 
impairment, contrast allergy, or too poor a state of health. This hardly endorses the 
notion that CTPA should be regarded as the primary screening test for the imaging 
of PE. Although CTPA has the advantage of being able to detect other lung diseases, 
it should be noted that V/Q scintigraphy can detect conditions other than PE [18].
V/Q scintigraphy in many countries continues to be done with planar imaging and 
using 133Xe as the ventilation agent. SPECT V/Q can be adequately performed with 
diethylenetriaminepentaacetic acid aerosols and in many in many countries. SPECT 
V/Q is clearly superior to planar imaging, and combined with recent developments 
in computing and camera hardware, V/Q SPECT also has the ability to quantify the 
extent of PE, and it is helpful in guiding treatment decisions [18]. Ventilation SPECT 
significantly increased the number of pregnant patients who could be classified as 
definitely positive or definitely negative. Only a minority of pregnant patients in the 
cohort had perfectly normal perfusion SPECT studies. A ventilation study is recom-
mended as part of SPECT scintigraphy in pregnancy to improve diagnostic accuracy 
and reporter confidence. It also has a lower radiation dose to the mother [18].
5. Management
Heparin (indirect thrombin inhibitors) remained the commonly used anticoagula-
tion medication in patients with thromboembolic phenomenon. It should be started 
when one suspected the diagnosis of pulmonary embolism. The advantages of unfrac-
tionated heparin (UFH) are shorter half-life, can be easily reversed, and have bigger 
molecular size; hence it cannot cross the placenta and no fetal adverse effects, and it 
is also not secreted into the breast milk. As there is increased blood volume during the 
pregnancy and peripartum period, increased heparin-binding proteins, and increased 
clearance of heparin through the renal system, the pregnant patient requires a higher 
dose of heparin to achieve the therapeutic levels. The dose of heparin may have to 
be increased to double to achieve the therapeutic effects [19]. The adverse effect of 
heparin, the fearsome, is the heparin-induced thrombocytopenia. It is divided into 
two types, the type 1 (also called heparin-associated thrombocytopenia or HAT) is 
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Figure 4. 
Treatment of pulmonary embolism in pregnancy and postpartum.
mainly benign condition and occurs due to negatively charged heparin that binds and 
destroys the positively charged platelets. HAT is a self-limiting clinical entity and does 
not require ant addition therapy. The HIT type 2 is immunologically mediated and can 
cause life-threatening thromboembolism, needs immunoassay or platelet aggregation 
test for diagnosis, and needs immediate stoppage of all forms of heparin to start direct 
thrombin inhibitors [20]. The osteopenia is another adverse effect of heparin use; 
it occurs due to inhibition of active metabolites of vitamin D. It increases the risk of 
fracture of the bones in pregnant patients [21].
5.1 Warfarin
Warfarin is a vitamin K antagonist commonly used anticoagulant in general 
population. It is a cost-effective medication. It is contraindicated in pregnancy as 
it crosses placenta and fetal teratogenic changes mainly the central nervous system 
defects. It also increases the risk of fetal miscarriages [22].
5.2 Thrombolysis and thrombectomy
In patients with massive pulmonary embolism causing hemodynamic dete-
riorations, hypoxia and right ventricular strain, immediate thrombolysis or 
thrombectomy is indicated (Figure 4) [16]. It may be associated with significant 
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bleeding risk in pregnant patients. A literature review found that the thrombo-
lytic therapy in pregnancy is having a lower maternal mortality of around 1% 
and premature delivery and fetal loss of around 6%, which is significantly lower 
to the embolectomy where the fetal loss is reported up to 40%. Thrombolytic 
agent plasminogen activator is preferred as it does not cross placenta and does 
not generate antibodies [23].
Saeed et al. reviewed 13 patients with peripartum pulmonary embolism reported 
between 1970 and 2012, age was ranging from 21 to 39 years, and the clinical mani-
festations of PE were respiratory and cardiac dyspnea in nine patients, tachycardia 
in five, cyanosis in four, tachypnea in four, hypoxemia in two, acute respiratory 
distress in one, and palpitations in one patient. Heparin at therapeutic doses in nine 
patients was insufficient to resolve their unstable hemodynamic conditions. In all 
13 patients, surgical pulmonary embolectomy was indicated because of rapidly 
worsening hemodynamics and cardiogenic shock. All patients underwent cardio-
pulmonary bypass. The thrombi were removed through an opening in the main PA 
in all patients. Two maternal deaths and three fetal deaths occurred leading to a 
15.4% maternal mortality rate and 23% fetal mortality rate [24].
5.3 Inferior vena cava (IVC) filter
The IVC filter is indicated in patients with whom systemic anticoagulation is 
contraindicated or patients with recurrent embolization and patients developing 
recurrent embolization in spite of systemic anticoagulation. IVC filter is not free 
from complications, which includes perforation and migration to the surrounding 
structures [23].
5.4 Supportive care and vasopressors
Respiratory distress and hemodynamic instability in patients with peripartum 
pulmonary embolism may need invasive ventilation and hemodynamic support 
with vasopressors. Treating physician should be well aware of physiological changes 
in pregnancy. Normal blood pressure and partial pressure of carbon dioxide are 
lower in pregnancy. The position of the patient being nursed is again of vital impor-
tance; patient should be in lateral position to avoid IVC compression by the gravid 
uterus. The vasopressor should be used judiciously as they decrease the blood flow 
in uteroplacental circulation, whereas the persistent hypotension also poses a seri-
ous risk for the vital organ functions [25].
6. Differential diagnosis
The PPE should be differentiated from community-acquired pneumonia and 
peripartum cardiomyopathy. The echocardiogram will help in ruling out peripar-
tum cardiomyopathy, and signs of sepsis will differentiate PPE from community-
acquired pneumonia.
7. Prevention
Peripartum thromboembolism common, as still the prophylaxis, is adequately 
administered in high-risk patients [5]. Those patients with a higher risk of throm-
boembolism during pregnancy and peripartum should receive the thromboprophy-
laxis to prevent proper thromboembolisms (Figure 5).
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8. Conclusion
The pregnant patients are at higher risk for VTE in all three trimester pregnancy, 
but in the postpartum period, they are at higher risk for the development of peripar-
tum pulmonary embolism (PPE). The physiological changes of pregnancy and nor-
mal or surgical delivery will form Virchow’s triad, hence increasing the risk of VTE by 
20-folds. It is important to diagnose early and manage it properly to avoid increase in 
morbidity and mortality in these special groups of patients. The risk factors for VTE 
and pulmonary embolism in these patients are broadly categorized into high risk, 
obstetric risk, and transient risk factors. The diagnosis is an important aspect of the 
management of VTE and PPE. As the misdiagnosis will increase the morbidity and 
mortality, wrong diagnosis will expose these patients for unnecessary risk of hemor-
rhagic complications of the anticoagulant use. We have to consider the ration hazard 
to the fetus and mother, but at the same time, one should not deprive the mother of 
accurate and early diagnosis of PPE for the fear of radiations. Compression USG, 
V/Q scan, and CTPA can be used for the diagnosis of VTE and PPE depending on the 
chest conditions. PPE has to be differentiated from community-acquired pneumonia 
and peripartum cardiomyopathy. Heparin is the anticoagulation of choice in VTE 
and PPE; if patients develop heparin-induced thrombocytopenia (HIT), the choice 
is direct thrombin inhibitors. Warfarin has the teratogenic effect; it should not be 
used during the pregnancy. Risk evaluation and strict use of thromboprophylaxis will 
prevent or decrease the incidence of PPE and VTE.
Figure 5. 
Treatment of pulmonary embolism in the peripartum period (modified from Bourjeily et al. [26]).
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